Brand-name drug · melanocortin 4 (MC4) receptor agonist

Imcivree (setmelanotide)

From the FDA label, read Published by PepVault

Imcivree is setmelanotide from Rhythm Pharmaceuticals, a once-daily shot that switches on the MC4 receptor, a brain receptor involved in hunger, fullness and how much energy the body burns.

FDA approved it to reduce excess body weight and keep it off long term in three rare kinds of obesity: acquired hypothalamic obesity from age 4, and Bardet-Biedl syndrome (BBS) or a POMC, PCSK1 or LEPR deficiency from age 2.

Active ingredient
Setmelanotide
Maker
Rhythm Pharmaceuticals
Class
melanocortin 4 (MC4) receptor agonist
FDA application
NDA 213793, first approved 2020

What FDA approved it for

Acquired hypothalamic obesity is weight gain after damage to the hypothalamus, the brain area that runs appetite. BBS is an inherited syndrome; POMC, PCSK1 and LEPR are genes in the same hunger pathway, and for them the label asks for a genetic test showing a harmful or uncertain variant.

The label rules out everyday obesity: Imcivree is not expected to work in general (polygenic) obesity, in obesity from other genetic syndromes, or where the gene change is classed as harmless.

From the label: 12.1 Mechanism of Action; 1 Indications and Usage.

How it is supplied

Imcivree’s forms and the doses each one gives, as the label lists them
FormDoses
Multiple-dose vial10 mg per vial

From the label: 3 Dosage Forms and Strengths.

The label’s dosing schedule

This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.

Acquired hypothalamic obesity, ages 6 and up, once a day

0.5 mg1 mg2 mg3 mg
Imcivree’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.
Acquired hypothalamic obesity, ages 6 and up, once a day: the steps on the label. Highest dose: 3 mg a day.
DoseWhen, on the label
0.5 mg a dayWeeks 1 and 2
1 mg a dayWeeks 3 and 4
2 mg a dayWeeks 5 and 6
3 mg a dayFrom week 7 on

The climb goes on only if the first dose is tolerated for 2 weeks; if it is not, the label stops the drug. Children aged 4 to under 6 have the same 0.5 mg first dose, and their rises follow a separate table on the label.

BBS or POMC, PCSK1 or LEPR deficiency, ages 12 and up, once a day

2 mg3 mg
Imcivree’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.
BBS or POMC, PCSK1 or LEPR deficiency, ages 12 and up, once a day: the steps on the label. Highest dose: 3 mg a day.
DoseWhen, on the label
2 mg a dayWeeks 1 and 2
3 mg a dayFrom week 3, if the first dose was tolerated

If 2 mg is not tolerated, the label drops to 1 mg and climbs back to 2 mg after a week; if 3 mg is too much, it settles at 2 mg.

Children aged 6 to under 12 begin lower, on 1 mg, and climb through 2 mg to the same 3 mg. Children aged 2 to under 6 begin on 0.5 mg, and the label sets their next dose by body weight.

Severe kidney disease changes the schedule: the label does not recommend Imcivree with end-stage kidney disease, and sets lower doses for some people with severe kidney impairment.

From the label: 2.2 Recommended Dosage in Patients with Acquired HO; 2.3 Recommended Dosage in Patients with BBS or POMC, PCSK1, or LEPR Deficiency; 2.4 Recommended Dosage in Patients with Renal Impairment.

How it’s taken

Imcivree is drawn from a vial and injected under the skin of the belly, thigh or arm once a day, at the beginning of the day, with or without food, in a different spot each day.

The vial comes out of the fridge about 15 minutes before the dose, or is warmed by rolling it gently between the palms for 60 seconds. Patients and caregivers are trained on the injection first.

The label asks for a full skin check before starting and from time to time during treatment, because Imcivree darkens the skin and moles in most people who take it; the darker skin fades once the drug is stopped.

From the label: 2.5 Administration Instructions; 5.4 Skin Hyperpigmentation, Darkening of Pre-Existing Nevi, and Development of New Melanocytic Nevi.

A smiling woman in a dark training top in her kitchen, holding a glass of water

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

If a dose is missed

A missed dose is not made up: the next dose comes at its usual time the next day, and the once-daily schedule carries on.

From the label: 2.5 Administration Instructions.

Storage

Unopened vials are kept in the fridge at 36°F to 46°F, in their carton. Out of the fridge, a vial keeps for up to 30 days at fridge to room temperature (up to 77°F), and an opened vial is thrown away after 30 days.

From the label: 16 How Supplied/Storage and Handling.

Side effects and warnings

Adverse reactions in at least 5% of people on Imcivree and more often than on placebo, in the trial of acquired hypothalamic obesity (ages 4 and up, 94 on Imcivree, 48 on placebo); the label prints this table as an image. Percent of people.
ReactionPlaceboImcivree
Darker skin (hyperpigmentation)1058
Nausea2555
Vomiting1938
Headache3137
New or darker moles615
Constipation612
Dizziness412
Sore throat (oropharyngeal pain)411

Darker skin was the most common change, in 58% against 10% on placebo. In the BBS trial’s 14 weeks against placebo, it was 67% against 0%, and vomiting 11% against 0%.

Spontaneous erections were reported in 7% of people on Imcivree and 4% on placebo in the hypothalamic obesity trial.

The other warnings

Imcivree has no boxed warning. Its warnings cover sexual side effects (an erection lasting over 4 hours needs emergency care), depression and suicidal thoughts, serious allergic reactions, darker skin and moles, and, in hypothalamic obesity, sudden adrenal insufficiency and swings in blood sodium in people who also have central diabetes insipidus.

From the label: 6.1 Clinical Trials Experience; 5 Warnings and Precautions.

What else we have on setmelanotide

Questions about Imcivree

What is the dose of Imcivree?

It depends on the condition and age. For acquired hypothalamic obesity from age 6, the label climbs from 0.5 mg a day to 3 mg a day by week 7; for BBS or POMC, PCSK1 or LEPR deficiency from age 12, it starts at 2 mg and moves to 3 mg after 2 weeks. A prescriber sets the dose.

Is Imcivree approved for ordinary weight loss?

No. Its label limits it to acquired hypothalamic obesity, Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiency, and says it is not expected to work in general obesity.

Does Imcivree darken the skin?

Often. In the hypothalamic obesity trial, 58% had darker skin against 10% on placebo, and the label says it fades once the drug is stopped. A skin check before and during treatment is part of the label.

What if a dose of Imcivree is missed?

The label skips it: the next dose comes at the usual time and the once-daily schedule goes on.

How is Imcivree stored?

Unopened vials go in the fridge at 36°F to 46°F. Out of the fridge, a vial keeps up to 30 days, and an opened vial is thrown away after 30 days.

Sources

PepVault is not affiliated with Rhythm Pharmaceuticals. Imcivree is a trademark of its owner.

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo